ReviewWorld journal of clinical oncology2025
Enhanced recovery after surgery protocols in gastrectomy with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer.
Review in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer with peritoneal carcinomatosis (PC) remains a formidable challenge in oncological care, especially regarding surgical intervention. Integrating enhanced recovery after surgery (ERAS) protocols into gastrectomy with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy has emerged as a promising approach. This minireview explores the influence of ERAS on surgical and oncological outcomes in this multifaceted procedure. Recent evidence suggests that ERAS, comprising multimodal strategies, improves postoperative recovery, reduces complications, and enhances quality of life. It may also contribute to better survival outcomes by minimizing perioperative morbidity and thereby facilitating the timely initiation of adjuvant therapy. Mechanistically, ERAS promotes early mobilization, attenuates postoperative immunosuppression, and supports timely adjuvant therapies, which are crucial in managing carcinomatosis. This minireview underscores the importance of multidisciplinary collaboration and individualized patient care to maximize ERAS benefits. Large-scale, prospective investigations are warranted to validate these findings and refine ERAS protocols for this specialized patient cohort. Further research will facilitate ongoing advancements in oncological surgery and perioperative care, ultimately improving outcomes for patients with gastric cancer and PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.